Establishment Labs (ESTA) has taken the breast implant industry by storm with its next level technology, 6th generation, Motiva Implants.
The reoperation rate is under 1% with a Motiva implant, no Motiva patient has gotten lymphoma, and the Motiva Ergonomix implants are a game changer.
A recent bearish report on ESTA discussed its related party transactions and an allegedly biased clinical study. But we conclude that these are not a big deal.
The FDA recently sent a warning letter about breast implant safety, which we believe will help ESTA because studies show its implants have a lower number of adverse events.
The breast implant industry is growing, and the growth rate could increase on a new perception of safety from Motiva implants.
Read the whole article on Seeking Alpha here.